RATIONALE: 2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]methyl)phenol (25CN-NBOH) is structurally similar to N-benzyl substituted phenethylamine hallucinogens currently emerging as drugs of abuse. 25CN-NBOH exhibits dramatic selectivity for 5-HT2A receptors in vitro, but has not been behaviorally characterized. OBJECTIVE: 25CN-NBOH was compared to the traditional phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) using mouse models of drug-elicited head twitch behavior and drug discrimination. METHODS: Drug-elicited head twitches were quantified for 10 min following administration of various doses of either DOI or 25CN-NBOH, with and without pretreatments of 0.01 mg/kg 5-HT2A antagonist M100907 or 3.0 mg/kg 5-HT2C antagonist RS102221. The capacity of 25CN-NBOH to attenuate DOI-elicited head twitch was also investigated. Mice were trained to discriminate DOI or M100907 from saline, and 25CN-NBOH was tested for generalization. RESULTS: 25CN-NBOH induced a head twitch response in the mouse that was lower in magnitude than that of DOI, blocked by M100907, but not altered by RS102221. DOI-elicited head twitch was dose-dependently attenuated by 25CN-NBOH pretreatment. 25CN-NBOH produced an intermediate degree of generalization (55 %) for the DOI training dose, and these interoceptive effects were attenuated by M100907. Finally, 25CN-NBOH did not generalize to M100907 at any dose, but ketanserin fully substituted in these animals. CONCLUSIONS: 25CN-NBOH was behaviorally active, but less effective than DOI in two mouse models of hallucinogenic effects. The effectiveness with which M100907 antagonized the behavioral actions of 25CN-NBOH strongly suggests that the 5-HT2A receptor is an important site of agonist action for this compound in vivo.
RATIONALE: 2-([2-(4-cyano-2,5-dimethoxyphenyl)ethylamino]methyl)phenol (25CN-NBOH) is structurally similar to N-benzyl substituted phenethylamine hallucinogens currently emerging as drugs of abuse. 25CN-NBOH exhibits dramatic selectivity for 5-HT2A receptors in vitro, but has not been behaviorally characterized. OBJECTIVE:25CN-NBOH was compared to the traditional phenethylamine hallucinogen R(-)-2,5-dimethoxy-4-iodoamphetamine (DOI) using mouse models of drug-elicited head twitch behavior and drug discrimination. METHODS: Drug-elicited head twitches were quantified for 10 min following administration of various doses of either DOI or 25CN-NBOH, with and without pretreatments of 0.01 mg/kg 5-HT2A antagonist M100907 or 3.0 mg/kg 5-HT2C antagonist RS102221. The capacity of 25CN-NBOH to attenuate DOI-elicited head twitch was also investigated. Mice were trained to discriminate DOI or M100907 from saline, and 25CN-NBOH was tested for generalization. RESULTS:25CN-NBOH induced a head twitch response in the mouse that was lower in magnitude than that of DOI, blocked by M100907, but not altered by RS102221. DOI-elicited head twitch was dose-dependently attenuated by 25CN-NBOH pretreatment. 25CN-NBOH produced an intermediate degree of generalization (55 %) for the DOI training dose, and these interoceptive effects were attenuated by M100907. Finally, 25CN-NBOH did not generalize to M100907 at any dose, but ketanserin fully substituted in these animals. CONCLUSIONS:25CN-NBOH was behaviorally active, but less effective than DOI in two mouse models of hallucinogenic effects. The effectiveness with which M100907 antagonized the behavioral actions of 25CN-NBOH strongly suggests that the 5-HT2A receptor is an important site of agonist action for this compound in vivo.
Authors: Thomas H McLean; Jason C Parrish; Michael R Braden; Danuta Marona-Lewicka; Alejandra Gallardo-Godoy; David E Nichols Journal: J Med Chem Date: 2006-09-21 Impact factor: 7.446
Authors: David E Nichols; Stewart P Frescas; Benjamin R Chemel; Kenneth S Rehder; Desong Zhong; Anita H Lewin Journal: Bioorg Med Chem Date: 2008-04-25 Impact factor: 3.641
Authors: W E Fantegrossi; J Simoneau; M S Cohen; S M Zimmerman; C M Henson; K C Rice; J H Woods Journal: J Pharmacol Exp Ther Date: 2010-09-21 Impact factor: 4.030
Authors: Jun-Xu Li; Alison Unzeitig; Martin A Javors; Kenner C Rice; Wouter Koek; Charles P France Journal: J Pharmacol Exp Ther Date: 2009-08-17 Impact factor: 4.030
Authors: Amy J Eshleman; Katherine M Wolfrum; John F Reed; Sunyoung O Kim; Robert A Johnson; Aaron Janowsky Journal: Biochem Pharmacol Date: 2018-09-25 Impact factor: 5.858
Authors: Adam L Halberstadt; Jochem V F van der Zee; Muhammad Chatha; Mark A Geyer; Susan B Powell Journal: Psychopharmacology (Berl) Date: 2018-11-17 Impact factor: 4.530
Authors: Kuglae Kim; Tao Che; Ouliana Panova; Jeffrey F DiBerto; Jiankun Lyu; Brian E Krumm; Daniel Wacker; Michael J Robertson; Alpay B Seven; David E Nichols; Brian K Shoichet; Georgios Skiniotis; Bryan L Roth Journal: Cell Date: 2020-09-17 Impact factor: 41.582
Authors: Joshua S Elmore; Ann M Decker; Agnieszka Sulima; Kenner C Rice; John S Partilla; Bruce E Blough; Michael H Baumann Journal: Neuropharmacology Date: 2018-03-01 Impact factor: 5.250
Authors: Grant C Glatfelter; Michael R Chojnacki; Shelby A McGriff; Tianpeng Wang; Michael H Baumann Journal: ACS Pharmacol Transl Sci Date: 2022-04-08
Authors: Adam L Halberstadt; Ivan S Sindhunata; Kees Scheffers; Aaron D Flynn; Richard F Sharp; Mark A Geyer; Jared W Young Journal: Neuropharmacology Date: 2016-03-25 Impact factor: 5.250
Authors: Christian B M Poulie; Anders A Jensen; Adam L Halberstadt; Jesper L Kristensen Journal: ACS Chem Neurosci Date: 2019-11-12 Impact factor: 5.780